January 23, 2009
View Full PaperErythropoietin treatment in patients with chronic heart failure: a meta-analysis
Key Points
Key points are not available for this paper at this time.
Abstract
In chronic HF, treatment with ESPs is not associated with a higher mortality rate or more adverse events, whereas a beneficial effect on HF hospitalisation is seen. These outcomes are in contrast with studies in cancer and kidney disease, and support a large phase III morbidity and mortality trial of anaemia correction in patients with chronic HF.